QTRX: Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024Quartr·21 hours agoAKYA0.00%QTRX+2.05%
Quanterix Warns of Broad Risk Exposure Despite No New Material Changes in Latest 10-QTip Ranks·2 days ago, 01:01 AMQTRX+2.05%
Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q SummaryTradingView·Aug 10 at 07:41 AMQTRX+2.05%AKYA0.00%
QTRX: Revenue up 34% year-over-year, but 2026 outlook lowered amid market softness and execution challengesQuartr·Aug 10 at 07:16 AMQTRX+2.05%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Aug 10 at 07:06 AMQTRX+2.05%SION-1.36%
Quanterix management participates in Canaccord Genuity Growth Conference fireside chatPUBT·Aug 6 at 07:07 AMQTRX+2.05%
